Clevidipine is an intravenous (IV) dihydropyridine calcium channel blocker indicated for acute hypertension and perioperative blood pressure control. Approved by the FDA in 2008 under brand name Cleviprex, it has a targeted market primarily in hospital and critical care settings.

Market Size and Growth Drivers

Global Market Estimate

As of 2022, the global intravenous antihypertensive drugs market was valued at approximately $1.2 billion. Clevidipine holds a fractional share but is considered significant within the niche of rapidly acting IV antihypertensives.

Market Penetration Factors

Clinical Preference: Clevidipine is favored over alternatives such as nicardipine or labetalol for its rapid onset and short half-life.
Physician Adoption: Limited to hospitals equipped for IV infusion; requires specialized administration.
Regulatory Environment: Post-approval, it has faced restricted labeling in some regions (e.g., EU), limiting geographic expansion.

Market Growth Drivers

Increasing prevalence of perioperative hypertension.
Growing demand for fast-acting blood pressure management solutions in critical care.
Adoption in surgical settings and hypertensive emergencies.
Rising surgical volumes globally, especially in Asia-Pacific.

Competitive Landscape

Competitors	Market Share	Key Attributes
Nicardipine (cardene)	Largest	Longer half-life, more administration flexibility
Labetalol	Significant	Oral and IV options, broader indications
Clevidipine	Niche player	Rapid action, short half-life, infusion control

Clevidipine's unique pharmacokinetic profile diminishes exposure duration, which reduces hypotension risk and makes it suitable for specific clinical scenarios where rapid titration is necessary.

Regulatory and Reimbursement Factors

FDA Approval: 2008; considerations included safety profile and administration protocols.
Market Access: Restricted in some countries due to concerns over lipid emulsion formulation and potential injection site risks.
Reimbursement: Generally covered under hospital outpatient and inpatient services, though cost considerations limit widespread use.

Financial Trajectory and Revenue Trends

Historical Revenue Data

Initial Launch: Estimated at $50 million in 2008.
2012-2015: Revenue stabilization around $70 million annually.
Post-2015: Slight decline attributed to competition and restricted usage.

Current Revenue Outlook

As of 2022, annual sales estimated between $40 million to $50 million in the U.S.
Marginal growth expected if regulatory hurdles are addressed and adoption expands in Asia-Pacific.

Pricing and Cost Structure

Average Price: About $150-$200 per vial in the U.S.
Cost Factors:
- Manufacturing complexity due to lipid emulsion formulation.
- Distribution costs tied to hospital-based use.
- R&D costs amortized over product life, with ongoing post-marketing commitments.

Market Challenges and Opportunities

Challenges

Limited to hospital settings; does not serve outpatient markets.
Competition from oral antihypertensives for post-stabilization management.
Regulatory restrictions that vary by region.

Opportunities

Expansion in emerging markets with increasing surgical volumes.
Potential label updates for broader indications.
Strategic partnerships to improve manufacturing efficiency and global distribution.

Future Outlook and Strategic Considerations

The outlook hinges on regulatory developments and clinical advocacy. Companies could focus on:

Conducting new clinical trials to demonstrate benefits over competitors in specific populations.
Targeting high-acuity hospital settings, emphasizing the rapid onset and short duration.
Addressing regulatory restrictions in Europe and other regions through data submissions.

Revenue projection remains modest unless broader adoption is realized; growth rates are expected to be under 5% annually unless significant market expansion occurs.

Key Takeaways

Clevidipine operates within a niche of IV antihypertensive drugs, primarily in hospital settings.
Market size in 2022 is approximately $50 million in the U.S., with limited global penetration.
Competition from nicardipine and labetalol influences sales, with price points around $150-$200 per vial.
Growth opportunities depend on regulatory access, clinical benefits, and geographic expansion.
Revenue stability currently relies on hospital-based prescriptions, with growth prospects tied to new clinical data and market expansion efforts.

FAQs

1. What are the primary clinical advantages of clevidipine?
It provides rapid blood pressure control with a short half-life, enabling precise titration and minimizing hypotension risk, making it ideal for critical care and perioperative use.

2. How does clevidipine compare to nicardipine?
Clevidipine has a shorter half-life (about 1 minute) versus nicardipine (which lasts several hours), allowing faster titration. Nicardipine can be more suitable for prolonged infusion scenarios.

3. What are the main regulatory challenges facing clevidipine?
Regulatory restrictions exist in some markets due to lipid emulsion formulation concerns and infusion site reactions, limiting broader international use.

4. Can clevidipine be used outside hospital settings?
No. Its administration requires specialized infusion equipment and monitoring, restricting use to hospital facilities.

5. Are there potential future indications for clevidipine?
While currently limited to hypertension management, research may explore additional indications such as use in hypertensive crises or neurocritical care, contingent on clinical trial evidence.

References

MarketWatch. (2022). "Intravenous antihypertensive drugs market size, share, growth."
FDA. (2008). "Approval letter for Cleviprex (clevidipine)."
EvaluatePharma. (2022). "Pharmaceutical sales data."
GlobalData Healthcare. (2022). "Market analysis: IV antihypertensive drugs."
Epocrates. (2022). "Clinical use and pharmacokinetics of clevidipine."

International Patents:	26
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	113
Clinical Trials:	27
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for Clevidipine
What excipients (inactive ingredients) are in Clevidipine?	Clevidipine excipients list
DailyMed Link:	Clevidipine at DailyMed

Drug Class	Dihydropyridine Calcium Channel Blocker
Mechanism of Action	Calcium Channel Antagonists

Clevidipine - Generic Drug Details

What are the generic sources for clevidipine and what is the scope of patent protection?

Summary for Clevidipine

Recent Clinical Trials for Clevidipine

Pharmacology for Clevidipine

Anatomical Therapeutic Chemical (ATC) Classes for Clevidipine

Paragraph IV (Patent) Challenges for CLEVIDIPINE

US Patents and Regulatory Information for Clevidipine

Expired US Patents for Clevidipine

International Patents for Clevidipine

Supplementary Protection Certificates for Clevidipine

Market Dynamics and Financial Trajectory of Clevidipine